{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:45:50Z","timestamp":1776771950214,"version":"3.51.2"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/HRD\/35\/02\/2006"],"award-info":[{"award-number":["BT\/HRD\/35\/02\/2006"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04121-7","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:14:59Z","timestamp":1763536499000},"page":"1484-1500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management"],"prefix":"10.1007","volume":"28","author":[{"given":"Abdul","family":"Wasai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7584-8872","authenticated-orcid":false,"given":"Adhiraj","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti","family":"Pandita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"4121_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers15020461","volume":"15","author":"P Posdzich","year":"2023","unstructured":"Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, et al. Metastatic prostate cancer\u2014a review of current treatment options and promising new approaches. Cancers (Basel). 2023;15:461.","journal-title":"Cancers (Basel)"},{"key":"4121_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CU9.0000000000000145","volume":"16","author":"A Tidd-Johnson","year":"2022","unstructured":"Tidd-Johnson A, Sebastian SA, Co EL, Afaq M, Kochhar H, Sheikh M, et al. Prostate cancer screening: continued controversies and novel biomarker advancements. Curr Urol. 2022;16:197.","journal-title":"Curr Urol"},{"key":"4121_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.semradonc.2025.05.004","volume":"35","author":"V Dragonetti","year":"2025","unstructured":"Dragonetti V, Colandrea M, Travaini L, Air\u00f2 Farulla LS, Ceci F, Mattana F. PSMA-PET guided radiotherapy in prostate cancer: a critical review of current applications and future directions. Semin Radiat Oncol. 2025;35:317\u201324.","journal-title":"Semin Radiat Oncol"},{"key":"4121_CR4","unstructured":"Study Details | NCT05160597 | Image-Guided (68Ga-PSMA-11 PET\/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative\/Inconclusive Biopsy | ClinicalTrials.gov, (n.d.)."},{"issue":"1","key":"4121_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(1):198.","journal-title":"Signal Transduct Target Ther"},{"key":"4121_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines13081837","volume":"13","author":"SA Jajja","year":"2025","unstructured":"Jajja SA, Sodhi N, Parent EE, Singh P. PSMA-directed theranostics in prostate cancer. Biomedicines. 2025;13:1\u201326.","journal-title":"Biomedicines"},{"key":"4121_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:1051\u201361.","journal-title":"J Clin Oncol"},{"key":"4121_CR8","first-page":"721","volume":"71","author":"C Quicios-Dorado","year":"2018","unstructured":"Quicios-Dorado C, Bolufer-Moragues E, Gomis-Goti C, Cabello-Benavente R, Cannata-Ortiz PJ, Gonzalez-Enguita C. Aggressive variants of castration resistant prostate cancer (crpc): neuroendocrine prostate cancer. Arch Esp Urol. 2018;71:721\u201334.","journal-title":"Arch Esp Urol"},{"key":"4121_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","volume":"530","author":"J Kang","year":"2022","unstructured":"Kang J, La Manna F, Bonollo F, Sampson N, Alberts IL, Mingels C, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156\u201369.","journal-title":"Cancer Lett"},{"key":"4121_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"4121_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-024-12783-9","volume":"24","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Lai C, Hu J, Mulati Y, Xu X, Luo J, et al. Integrative analysis regarding the correlation between collagen-related genes and prostate cancer. BMC Cancer. 2024;24:1\u201312.","journal-title":"BMC Cancer"},{"key":"4121_CR12","volume":"16","author":"M Basheeruddin","year":"2024","unstructured":"Basheeruddin M, Qausain S. Hypoxia-inducible factor 1-alpha (HIF-1\u03b1) and cancer: mechanisms of tumor hypoxia and therapeutic targeting. Cureus. 2024;16:e70700.","journal-title":"Cureus"},{"key":"4121_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.molmed.2025.03.015","volume":"31","author":"J Laaraj","year":"2025","unstructured":"Laaraj J, Lachance G, Bergeron A, Fradet Y, Robitaille K, Fradet V. New insights into gut microbiota\u2013prostate cancer crosstalk. Trends Mol Med. 2025;31:778\u2013800.","journal-title":"Trends Mol Med"},{"key":"4121_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.955669","volume":"10","author":"H Zhou","year":"2022","unstructured":"Zhou H, He Q, Li C, Alsharafi BLM, Deng L, Long Z, et al. Focus on the tumor microenvironment: a seedbed for neuroendocrine prostate cancer. Front Cell Dev Biol. 2022;10:955669. https:\/\/doi.org\/10.3389\/fcell.2022.955669.","journal-title":"Front Cell Dev Biol"},{"key":"4121_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","volume":"380","author":"D Aldinucci","year":"2016","unstructured":"Aldinucci D, Celegato M, Casagrande N. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Cancer Lett. 2016;380:243\u201352.","journal-title":"Cancer Lett"},{"key":"4121_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ebiom.2016.03.022","volume":"7","author":"L Wang","year":"2016","unstructured":"Wang L, Wang J, Xiong H, Wu F, Lan T, Zhang Y, et al. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer. EBioMedicine. 2016;7:50\u201361.","journal-title":"EBioMedicine"},{"key":"4121_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.semcancer.2018.09.003","volume":"57","author":"N Howard","year":"2019","unstructured":"Howard N, Clementino M, Kim D, Wang L, Verma A, Shi X, et al. New developments in mechanisms of prostate cancer progression. Semin Cancer Biol. 2019;57:111\u20136.","journal-title":"Semin Cancer Biol"},{"key":"4121_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fchem.2019.00651","volume":"7","author":"A Zamagni","year":"2019","unstructured":"Zamagni A, Cortesi M, Zanoni M, Tesei A. Non-nuclear AR signaling in prostate cancer. Front Chem. 2019;7:1\u201311.","journal-title":"Front Chem"},{"key":"4121_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imm.13456","volume":"168","author":"D Feng","year":"2023","unstructured":"Feng D, Xiong Q, Wei Q, Yang L. Cellular landscape of tumour microenvironment in prostate cancer. Immunology. 2023;168:199\u2013202.","journal-title":"Immunology"},{"key":"4121_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejphar.2015.03.088","volume":"778","author":"G Marone","year":"2016","unstructured":"Marone G, Varricchi G, Loffredo S, Granata F. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol. 2016;778:146\u201351.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"4121_CR21","doi-asserted-by":"publisher","first-page":"a030510","DOI":"10.1101\/cshperspect.a030510","volume":"8","author":"C Levesque","year":"2018","unstructured":"Levesque C, Nelson PS. Cellular constituents of the prostate stroma: Key contributors to prostate cancer progression and therapy resistance. Cold Spring Harb Perspect Med. 2018;8(8):a030510.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4121_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","volume":"530","author":"J Kang","year":"2022","unstructured":"Kang J, La Manna F, Bonollo F, Sampson N, Alberts IL, Mingels C, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156\u201369. https:\/\/doi.org\/10.1016\/j.canlet.2022.01.015.","journal-title":"Cancer Lett"},{"key":"4121_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000505437","volume":"87","author":"A Sejda","year":"2020","unstructured":"Sejda A, Sigorski D, Gulczy\u0144ski J, Weso\u0142owski W, Kitli\u0144ska J, I\u017cycka-\u015awieszewska E. Complexity of neural component of tumor microenvironment in prostate cancer. Pathobiology. 2020;87:87\u201399.","journal-title":"Pathobiology"},{"issue":"1","key":"4121_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tranon.2019.10.001","volume":"13","author":"S Zhong","year":"2020","unstructured":"Zhong S, Jeong JH, Chen Z, Chen Z, Luo JL. Targeting tumor microenvironment by small-molecule inhibitors. Transl Oncol. 2020;13(1):57\u201369. https:\/\/doi.org\/10.1016\/j.tranon.2019.10.001.","journal-title":"Transl Oncol"},{"key":"4121_CR25","doi-asserted-by":"publisher","first-page":"T95","DOI":"10.1530\/ERC-21-0149","volume":"28","author":"JTW Kwon","year":"2021","unstructured":"Kwon JTW, Bryant RJ, Parkes EE. The tumor microenvironment and immune responses in prostate cancer patients. Endocr Relat Cancer. 2021;28:T95\u2013107.","journal-title":"Endocr Relat Cancer"},{"key":"4121_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0753-3","volume":"7","author":"CL Ihle","year":"2019","unstructured":"Ihle CL, Provera MD, Straign DM, Smith EE, Edgerton SM, Van Bokhoven A, et al. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. J Immunother Cancer. 2019;7:1\u20139.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4121_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2011.03.055","volume":"60","author":"C De Nunzio","year":"2011","unstructured":"De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schr\u00f6der F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60(1):106\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2011.03.055.","journal-title":"Eur Urol"},{"key":"4121_CR28","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","volume":"47","author":"T Ahrends","year":"2017","unstructured":"Ahrends T, Spanjaard A, Pilzecker B, B\u0105ba\u0142a N, Bovens A, Xiao Y, et al. CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. 2017;47:848-861.e5.","journal-title":"Immunity"},{"key":"4121_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trsl.2018.11.004","volume":"206","author":"MJ McAllister","year":"2019","unstructured":"McAllister MJ, Underwood MA, Leung HY, Edwards J. A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. Transl Res. 2019;206:91\u2013106.","journal-title":"Transl Res"},{"key":"4121_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21124449","volume":"21","author":"TO Adekoya","year":"2020","unstructured":"Adekoya TO, Richardson RM. Cytokines and chemokines as mediators of prostate cancer metastasis. Int J Mol Sci. 2020;21:1\u201329.","journal-title":"Int J Mol Sci"},{"key":"4121_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","volume":"20","author":"GV Sharonov","year":"2020","unstructured":"Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020;20:294\u2013307.","journal-title":"Nat Rev Immunol"},{"key":"4121_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958756","volume":"12","author":"R Tan","year":"2022","unstructured":"Tan R, Nie M, Long W. The role of B cells in cancer development. Front Oncol. 2022;12:958756.","journal-title":"Front Oncol"},{"key":"4121_CR33","doi-asserted-by":"publisher","first-page":"11825","DOI":"10.3390\/ijms252111825","volume":"25","author":"H Yang","year":"2024","unstructured":"Yang H, Zhang Z, Li J, Wang K, Zhu W, Zeng Y. The dual role of B cells in the tumor microenvironment: implications for cancer immunology and therapy. Int J Mol Sci. 2024;25:11825.","journal-title":"Int J Mol Sci"},{"key":"4121_CR34","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1182\/blood-2009-01-201467","volume":"113","author":"P Krebs","year":"2009","unstructured":"Krebs P, Barnes MJ, Lampe K, Whitley K, Bahjat KS, Beutler B, et al. NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood. 2009;113:6593\u2013602.","journal-title":"Blood"},{"key":"4121_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/pros.23479","volume":"78","author":"L Xu","year":"2018","unstructured":"Xu L, Shen M, Chen X, Zhu R, Yang DR, Tsai Y, et al. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1\/NKG2D ligand levels in tumor cells. Prostate. 2018;78:353\u201364.","journal-title":"Prostate"},{"key":"4121_CR36","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.3390\/ijms22136741","volume":"22","author":"E Shklovskaya","year":"2021","unstructured":"Shklovskaya E, Rizos H. MHC class I deficiency in solid tumors and therapeutic strategies to overcome it. Int J Mol Sci. 2021;22:6741.","journal-title":"Int J Mol Sci"},{"key":"4121_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000353316","volume":"99","author":"S Loffredo","year":"2014","unstructured":"Loffredo S, Staiano RI, Granata F, Genovese A, Marone G. Immune cells as a source and target of angiogenic and lymphangiogenic factors. Chem Immunol Allergy. 2014;99:15\u201336.","journal-title":"Chem Immunol Allergy"},{"issue":"1","key":"4121_CR38","first-page":"981434","volume":"2014","author":"BWC Tse","year":"2014","unstructured":"Tse BWC, Jovanovic L, Nelson CC, De Souza P, Power CA, Russell PJ. From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int. 2014;2014(1):981434.","journal-title":"Biomed Res Int"},{"key":"4121_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/path.5757","volume":"255","author":"LB Andersen","year":"2021","unstructured":"Andersen LB, N\u00f8rgaard M, Rasmussen M, Freds\u00f8e J, Borre M, Ulh\u00f8i BP, et al. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol. 2021;255:155\u201365.","journal-title":"J Pathol"},{"key":"4121_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-024-01559-0","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal JA, Per\u00e1n M, Giovannetti E. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. 2024;17:1\u201334.","journal-title":"J Hematol Oncol"},{"key":"4121_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","volume":"23","author":"M De Palma","year":"2013","unstructured":"De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23:277\u201386.","journal-title":"Cancer Cell"},{"key":"4121_CR42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933\u201359.","journal-title":"Cancer Discov"},{"issue":"1","key":"4121_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.canlet.2016.04.009","volume":"380","author":"SR Singh","year":"2016","unstructured":"Singh SR, Rameshwar P, Siegel P. Targeting tumor microenvironment in cancer therapy. Cancer Lett. 2016;380(1):203\u20134. https:\/\/doi.org\/10.1016\/j.canlet.2016.04.009.","journal-title":"Cancer Lett"},{"key":"4121_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9092051","volume":"9","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, et al. Is there a role for immunotherapy in prostate cancer? Cells. 2020;9:1\u201322.","journal-title":"Cells"},{"key":"4121_CR45","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1535-7163.MCT-19-0774","volume":"19","author":"B Hutchins","year":"2020","unstructured":"Hutchins B, Starling GC, McCoy MA, Herzyk D, Poulet FM, Dulos J, et al. Biophysical and immunological characterization and in vivo pharmacokinetics and toxicology in nonhuman primates of the anti-PD-1 antibody pembrolizumab. Mol Cancer Ther. 2020;19:1298\u2013307.","journal-title":"Mol Cancer Ther"},{"key":"4121_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/14712598.2018.1420777","volume":"18","author":"C Alaia","year":"2018","unstructured":"Alaia C, Boccellino M, Zappavigna S, Amler E, Quagliuolo L, Rossetti S, et al. Ipilimumab for the treatment of metastatic prostate cancer. Expert Opin Biol Ther. 2018;18:205\u201313.","journal-title":"Expert Opin Biol Ther"},{"key":"4121_CR47","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.annonc.2025.05.007","volume":"36","author":"JN Graff","year":"2025","unstructured":"Graff JN, Burotto M, Fong PC, Pook DW, Zurawski B, Manneh Kopp R, et al. Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study. Ann Oncol. 2025;36:976\u201387.","journal-title":"Ann Oncol"},{"key":"4121_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02041","author":"N Kim","year":"2018","unstructured":"Kim N, Kim HS. Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.02041.","journal-title":"Front Immunol"},{"key":"4121_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"S Muhammad","year":"2023","unstructured":"Muhammad S, Fan T, Hai Y, Gao Y, He J. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer. 2023;22:1\u201323.","journal-title":"Mol Cancer"},{"key":"4121_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fonc.2019.00241","volume":"9","author":"S Di","year":"2019","unstructured":"Di S, Zhou M, Pan Z, Sun R, Chen M, Jiang H, et al. Combined adjuvant of poly I:C improves antitumor effects of CAR-T cells. Front Oncol. 2019;9:241.","journal-title":"Front Oncol"},{"key":"4121_CR51","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1021\/acsnano.6b07195","volume":"11","author":"X Xu","year":"2017","unstructured":"Xu X, Wu J, Liu Y, Saw PE, Tao W, Yu M, et al. Multifunctional envelope-type siRNA delivery nanoparticle platform for prostate cancer therapy. ACS Nano. 2017;11:2618\u201327.","journal-title":"ACS Nano"},{"key":"4121_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1517\/14728220802705696","volume":"13","author":"E Jones","year":"2009","unstructured":"Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets. 2009;13:227\u201334.","journal-title":"Expert Opin Ther Targets"},{"key":"4121_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-023-11153-1","volume":"23","author":"E Nadal","year":"2023","unstructured":"Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, et al. A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer. 2023;23:1\u201313.","journal-title":"BMC Cancer"},{"key":"4121_CR54","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.18632\/oncotarget.23795","volume":"9","author":"JM Yingling","year":"2017","unstructured":"Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-\u03b2 receptor type I inhibitor. Oncotarget. 2017;9:6659.","journal-title":"Oncotarget"},{"key":"4121_CR55","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1158\/1078-0432.CCR-19-1338","volume":"25","author":"V Santini","year":"2019","unstructured":"Santini V, Valcarcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, et al. Phase II study of the ALK5 inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes. Clin Cancer Res. 2019;25:6976\u201385.","journal-title":"Clin Cancer Res"},{"key":"4121_CR56","unstructured":"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma, (n.d.)."},{"key":"4121_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"4121_CR58","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4172\/1948-5956.1000373","volume":"7","author":"V Singh","year":"2015","unstructured":"Singh V, Gupta D, Almasan A. Development of novel anti-Cd20 monoclonal antibodies and modulation in Cd20 levels on cell surface: looking to improve immunotherapy response. J Cancer Sci Ther. 2015;7(11):347.","journal-title":"J Cancer Sci Ther"},{"key":"4121_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","volume":"47","author":"T van Meerten","year":"2010","unstructured":"van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010;47:199\u2013210.","journal-title":"Semin Hematol"},{"key":"4121_CR60","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/S1470-2045(17)30605-8","volume":"18","author":"TM Beer","year":"2017","unstructured":"Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fl\u00e9chon A, et al. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph. Lancet Oncol. 2017;18:1532\u201342.","journal-title":"Lancet Oncol"},{"key":"4121_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.maturitas.2012.01.016","volume":"73","author":"V Sanna","year":"2012","unstructured":"Sanna V, Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Maturitas. 2012;73:27\u201332.","journal-title":"Maturitas"},{"issue":"4","key":"4121_CR62","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bju.13412","volume":"118","author":"RA Madan","year":"2016","unstructured":"Madan RA, Karzai FH, Ning YM, Adesunloye BA, Huang X, Harold N, et al. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. BJU Int. 2016;118(4):590\u20137.","journal-title":"BJU Int"},{"key":"4121_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02370-4","volume":"18","author":"ST Ryan","year":"2020","unstructured":"Ryan ST, Zhang J, Burner DN, Liss M, Pittman E, Muldong M, et al. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. J Transl Med. 2020;18:1\u201311.","journal-title":"J Transl Med"},{"key":"4121_CR64","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731-1743.e13.","journal-title":"Cell"},{"issue":"22","key":"4121_CR65","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.3390\/cancers14225719","volume":"14","author":"C Steinbach","year":"2022","unstructured":"Steinbach C, Merchant A, Zaharie AT, Horak P, Marhold M, Krainer M. Current developments in cellular therapy for castration resistant prostate cancer: a systematic review of clinical studies. Cancers. 2022;14(22):5719.","journal-title":"Cancers"},{"key":"4121_CR66","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2217\/imt.15.120","volume":"8","author":"L Hammerich","year":"2016","unstructured":"Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy. 2016;8:315\u201330.","journal-title":"Immunotherapy"},{"key":"4121_CR67","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DDDT.S141491","volume":"12","author":"I Faiena","year":"2018","unstructured":"Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018;12:209\u201315.","journal-title":"Drug Des Devel Ther"},{"key":"4121_CR68","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:697\u2013717.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"4121_CR69","first-page":"9720912","volume":"2016","author":"Q Guo","year":"2016","unstructured":"Guo Q, Jin Z, Yuan Y, Liu R, Xu T, Wei H, et al. New mechanisms of tumor-associated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy. J Immunol Res. 2016;2016(1):9720912.","journal-title":"J Immunol Res"},{"key":"4121_CR70","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462\u201372.","journal-title":"Cancer Cell"},{"key":"4121_CR71","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","volume":"28","author":"JD Brody","year":"2010","unstructured":"Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study. J Clin Oncol. 2010;28:4324\u201332.","journal-title":"J Clin Oncol"},{"issue":"17","key":"4121_CR72","doi-asserted-by":"publisher","first-page":"9550","DOI":"10.3390\/ijms22179550","volume":"22","author":"CM Melo","year":"2021","unstructured":"Melo CM, Vidotto T, Chaves LP, Lautert-Dutra W, Reis RBD, Squire JA. The role of somatic mutations on the immune response of the tumor microenvironment in prostate cancer. Int J Mol Sci. 2021;22(17):9550.","journal-title":"Int J Mol Sci"},{"key":"4121_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cpr.12918","volume":"53","author":"L Xia","year":"2020","unstructured":"Xia L, Sun J, Xie S, Chi C, Zhu Y, Pan J, et al. PRKAR2B-HIF-1\u03b1 loop promotes aerobic glycolysis and tumour growth in prostate cancer. Cell Prolif. 2020;53:1\u201313.","journal-title":"Cell Prolif"},{"key":"4121_CR74","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.2217\/nnm-2017-0236","volume":"12","author":"S Gupta","year":"2017","unstructured":"Gupta S, Gupta PK, Dharanivasan G, Verma RS. Current prospects and challenges of nanomedicine delivery in prostate cancer therapy. Nanomedicine. 2017;12:2675\u201392.","journal-title":"Nanomedicine"},{"key":"4121_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nano10091696","volume":"10","author":"M Barani","year":"2020","unstructured":"Barani M, Sabir F, Rahdar A, Arshad R, Kyzas GZ. Nanotreatment and nanodiagnosis of prostate cancer: recent updates. Nanomaterials. 2020;10:1\u201325.","journal-title":"Nanomaterials"},{"key":"4121_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27248659","author":"AA Rabaan","year":"2022","unstructured":"Rabaan AA, Bukhamsin R, AlSaihati H, Alshamrani SA, AlSihati J, Al-Afghani HM, et al. Recent trends and developments in multifunctional nanoparticles for cancer theranostics. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27248659.","journal-title":"Molecules"},{"key":"4121_CR77","first-page":"471","volume":"23","author":"J Li","year":"2023","unstructured":"Li J, Wang S, Fontana F, Tapeinos C, Shahbazi MA, Han H, et al. Nanoparticles-based phototherapy systems for cancer treatment: current status and clinical potential. Bioact Mater. 2023;23:471\u2013507.","journal-title":"Bioact Mater"},{"key":"4121_CR78","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221093146","author":"JH Kim","year":"2022","unstructured":"Kim JH, Oh E, Yun CW, Lee SH, Song YS. Carboxyl esterase-TRAIL expressing human adipose stem cells inhibit tumor growth in castration-resistant prostate cancer-bearing mice with less toxicity. Technol Cancer Res Treat. 2022. https:\/\/doi.org\/10.1177\/15330338221093146.","journal-title":"Technol Cancer Res Treat"},{"key":"4121_CR79","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1080\/10717544.2022.2110998","volume":"29","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu Z, Lu T, Luo J, Xue H. Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer. Drug Deliv. 2022;29:2705\u201312.","journal-title":"Drug Deliv"},{"issue":"2","key":"4121_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100502","volume":"3","author":"MA Rice","year":"2022","unstructured":"Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, et al. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Rep Med. 2022;3(2):100502. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100502.","journal-title":"Cell Rep Med"},{"key":"4121_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"A Akbarzadeh","year":"2013","unstructured":"Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:1\u20139.","journal-title":"Nanoscale Res Lett"},{"key":"4121_CR82","doi-asserted-by":"publisher","first-page":"38537","DOI":"10.1021\/acsami.9b14738","volume":"11","author":"PKB Nagesh","year":"2019","unstructured":"Nagesh PKB, Chowdhury P, Hatami E, Kumari S, Kashyap VK, Tripathi MK, et al. Cross-linked polyphenol-based drug nano-self-assemblies engineered to blockade prostate cancer senescence. ACS Appl Mater Interfaces. 2019;11:38537\u201354.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4121_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/nano12162826","author":"S Siddique","year":"2022","unstructured":"Siddique S, Chow JCL. Recent advances in functionalized nanoparticles in cancer theranostics. Nanomaterials. 2022. https:\/\/doi.org\/10.3390\/nano12162826.","journal-title":"Nanomaterials"},{"key":"4121_CR84","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1208\/s12249-014-0089-8","volume":"15","author":"A Babu","year":"2014","unstructured":"Babu A, Templeton AK, Munshi A, Ramesh R. Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer. AAPS PharmSciTech. 2014;15:709\u201321.","journal-title":"AAPS PharmSciTech"},{"key":"4121_CR85","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.arabjc.2017.05.011","volume":"12","author":"I Khan","year":"2019","unstructured":"Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arab J Chem. 2019;12:908\u201331.","journal-title":"Arab J Chem"},{"key":"4121_CR86","first-page":"21","volume":"57","author":"VK Lakshmanan","year":"2016","unstructured":"Lakshmanan VK. Therapeutic efficacy of nanomedicines for prostate cancer: an update. Korean J Urol. 2016;57:21\u20139.","journal-title":"Korean J Urol"},{"key":"4121_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100762","volume":"56","author":"L Cohen","year":"2021","unstructured":"Cohen L, Livney YD, Assaraf YG. Targeted nanomedicine modalities for prostate cancer treatment. Drug Resist Updat. 2021;56:100762.","journal-title":"Drug Resist Updat"},{"key":"4121_CR88","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.2174\/0929867325666171229141156","volume":"25","author":"S Bayda","year":"2017","unstructured":"Bayda S, Hadla M, Palazzolo S, Riello P, Corona G, Toffoli G, et al. Inorganic nanoparticles for cancer therapy: a transition from lab to clinic. Curr Med Chem. 2017;25:4269\u2013303.","journal-title":"Curr Med Chem"},{"key":"4121_CR89","doi-asserted-by":"publisher","first-page":"109891","DOI":"10.1016\/j.msec.2019.109891","volume":"104","author":"W Wei","year":"2019","unstructured":"Wei W, Zhang X, Zhang S, Wei G, Su Z. Biomedical and bioactive engineered nanomaterials for targeted tumor photothermal therapy: a review. Mater Sci Eng C. 2019;104:109891.","journal-title":"Mater Sci Eng C"},{"key":"4121_CR90","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/1872210511666171101120157","volume":"12","author":"S Thambiraj","year":"2017","unstructured":"Thambiraj S, Hema S, Shankaran DR. An overview on applications of gold nanoparticle for early diagnosis and targeted drug delivery to prostate cancer. Recent Pat Nanotechnol. 2017;12:110\u201331.","journal-title":"Recent Pat Nanotechnol"},{"key":"4121_CR91","doi-asserted-by":"crossref","unstructured":"Tiwari PM, Bawage SS, Singh SR, Gold nanoparticles and their applications in photomedicine, diagnosis and therapy. Appl Nanosci Photomed 2015; 249\u2013266.","DOI":"10.1533\/9781908818782.249"},{"key":"4121_CR92","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2010-03-274258","volume":"116","author":"L Agemy","year":"2010","unstructured":"Agemy L, Sugahara KN, Kotamraju VR, Gujraty K, Girard OM, Kono Y, et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood. 2010;116:2847\u201356.","journal-title":"Blood"},{"key":"4121_CR93","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.7150\/thno.43631","volume":"10","author":"D Wu","year":"2020","unstructured":"Wu D, Zhu ZQ, Tang HX, Shi ZE, Kang J, Liu Q, et al. Efficacy-shaping nanomedicine by loading calcium peroxide into tumor microenvironment-responsive nanoparticles for the antitumor therapy of prostate cancer. Theranostics. 2020;10:9808\u201329.","journal-title":"Theranostics"},{"key":"4121_CR94","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.drudis.2017.04.018","volume":"22","author":"P Chowdhury","year":"2017","unstructured":"Chowdhury P, Roberts AM, Khan S, Hafeez BB, Chauhan SC, Jaggi M, et al. Magnetic nanoformulations for prostate cancer. Drug Discov Today. 2017;22:1233\u201341.","journal-title":"Drug Discov Today"},{"key":"4121_CR95","first-page":"1","volume":"2","author":"L He","year":"2019","unstructured":"He L, Liu J, Li S, Feng X, Wang C, Zhuang X, et al. Polymer nanoplatforms at work in prostate cancer therapy. Adv Ther. 2019;2:1\u201325.","journal-title":"Adv Ther"},{"key":"4121_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/bioengineering7030091","volume":"7","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Hushmandi K, Moghadam ER, Zarrin V, Kashani SH, Bokaie S, et al. Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. Bioengineering. 2020;7:1\u201340.","journal-title":"Bioengineering"},{"key":"4121_CR97","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0748233717747472","volume":"34","author":"AP Francis","year":"2018","unstructured":"Francis AP, Devasena T. Toxicity of carbon nanotubes: a review. Toxicol Ind Health. 2018;34:200\u201310.","journal-title":"Toxicol Ind Health"},{"key":"4121_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.carbon.2013.08.038","volume":"65","author":"A Bianco","year":"2013","unstructured":"Bianco A, Cheng HM, Enoki T, Gogotsi Y, Hurt RH, Koratkar N, et al. All in the graphene family - a recommended nomenclature for two-dimensional carbon materials. Carbon. 2013;65:1\u20136.","journal-title":"Carbon"},{"key":"4121_CR99","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/1568026619666190125145836","volume":"19","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wang L, You X, Xian T, Wu J, Pang J. Nanoparticle therapy for prostate cancer: overview and perspectives. Curr Top Med Chem. 2019;19:57\u201373.","journal-title":"Curr Top Med Chem"},{"key":"4121_CR100","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.2147\/IJN.S239548","volume":"15","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang Y, Cai G, Li Q. Exosomes as actively targeted nanocarriers for cancer therapy. Int J Nanomedicine. 2020;15:4257\u201373.","journal-title":"Int J Nanomedicine"},{"key":"4121_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110181","volume":"127","author":"Y Chen","year":"2020","unstructured":"Chen Y, Deng Y, Zhu C, Xiang C. Anti prostate cancer therapy: aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles. Biomed Pharmacother. 2020;127:110181.","journal-title":"Biomed Pharmacother"},{"key":"4121_CR102","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1007\/s11095-015-1662-x","volume":"32","author":"W Hariri","year":"2015","unstructured":"Hariri W, Sudha T, Bharali DJ, Cui H, Mousa SA. Nano-targeted delivery of toremifene, an estrogen receptor-\u03b1 blocker in prostate cancer. Pharm Res. 2015;32:2764\u201374.","journal-title":"Pharm Res"},{"key":"4121_CR103","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378.","journal-title":"Eur Urol"},{"key":"4121_CR104","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jconrel.2015.09.029","volume":"219","author":"C He","year":"2015","unstructured":"He C, Lu J, Lin W. Hybrid nanoparticles for combination therapy of cancer. J Control Release. 2015;219:224\u201336.","journal-title":"J Control Release"},{"key":"4121_CR105","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","volume":"51","author":"L Eckhoff","year":"2015","unstructured":"Eckhoff L, Knoop A, Jensen M, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51:292\u2013300.","journal-title":"Eur J Cancer"},{"key":"4121_CR106","first-page":"117","volume":"5","author":"CJ Paller","year":"2011","unstructured":"Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117.","journal-title":"Drug Des Devel Ther"},{"key":"4121_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100762","author":"L Cohen","year":"2021","unstructured":"Cohen L, Livney YD, Assaraf YG. Targeted nanomedicine modalities for prostate cancer treatment. Drug Resist Updat. 2021. https:\/\/doi.org\/10.1016\/j.drup.2021.100762.","journal-title":"Drug Resist Updat"},{"key":"4121_CR108","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.acr.2018.05.001","volume":"139","author":"DM Connor","year":"2018","unstructured":"Connor DM, Broome AM. Gold nanoparticles for the delivery of cancer therapeutics. Adv Cancer Res. 2018;139:163\u201384.","journal-title":"Adv Cancer Res"},{"key":"4121_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201903441","volume":"7","author":"TA Tabish","year":"2020","unstructured":"Tabish TA, Dey P, Mosca S, Salimi M, Palombo F, Matousek P, et al. Smart gold nanostructures for light mediated cancer theranostics: combining optical diagnostics with photothermal therapy. Adv Sci. 2020;7:1903441.","journal-title":"Adv Sci"},{"key":"4121_CR110","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/imt-2018-0029","volume":"10","author":"Y Liu","year":"2018","unstructured":"Liu Y, Crawford BM, Vo-Dinh T. Gold nanoparticles-mediated photothermal therapy and immunotherapy. Immunotherapy. 2018;10:1175\u201388.","journal-title":"Immunotherapy"},{"key":"4121_CR111","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373\u201387.","journal-title":"Pharm Res"},{"key":"4121_CR112","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.msec.2015.11.067","volume":"60","author":"F Masood","year":"2016","unstructured":"Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C Mater Biol. 2016;60:569\u201378.","journal-title":"Mater Sci Eng C Mater Biol"},{"issue":"4","key":"4121_CR113","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3390\/polym11040745","volume":"11","author":"R Rai","year":"2019","unstructured":"Rai R, Alwani S, Badea I. Polymeric nanoparticles in gene therapy: New avenues of design and optimization for delivery applications. Polymers. 2019;11(4):745.","journal-title":"Polymers"},{"issue":"9","key":"4121_CR114","doi-asserted-by":"publisher","first-page":"6408","DOI":"10.1002\/jcp.26593","volume":"233","author":"NH Farina","year":"2018","unstructured":"Farina NH, Zingiryan A, Vrolijk MA, Perrapato SD, Ades S, Stein GS, et al. Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention. J Cell Physiol. 2018;233(9):6408\u201317. https:\/\/doi.org\/10.1002\/jcp.26593.","journal-title":"J Cell Physiol"},{"key":"4121_CR115","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.5114\/aoms.2016.62911","volume":"12","author":"F Shahabipour","year":"2016","unstructured":"Shahabipour F, Banach M, Sahebkar A. Exosomes as nanocarriers for siRNA delivery: paradigms and challenges. Arch Med Sci. 2016;12:1324\u20136.","journal-title":"Arch Med Sci"},{"key":"4121_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nano12030524","volume":"12","author":"A Gorshkov","year":"2022","unstructured":"Gorshkov A, Purvinsh L, Brodskaia A, Vasin A. Exosomes as natural nanocarriers for RNA-based therapy and prophylaxis. Nanomaterials. 2022;12:1\u201324.","journal-title":"Nanomaterials"},{"key":"4121_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2025.100390","author":"MR Fadaei","year":"2025","unstructured":"Fadaei MR, Fadaei MS, Kheirieh AE, Hatami H, Rahmanian-Devin P, Tayebi-Khorrami V, et al. Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications. Int J Pharm: X. 2025. https:\/\/doi.org\/10.1016\/j.ijpx.2025.100390.","journal-title":"Int J Pharm: X"},{"key":"4121_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s40580-019-0193-2","author":"PN Navya","year":"2019","unstructured":"Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Convergence. 2019. https:\/\/doi.org\/10.1186\/s40580-019-0193-2.","journal-title":"Nano Convergence"},{"key":"4121_CR119","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.bios.2019.03.065","volume":"137","author":"S Singh","year":"2019","unstructured":"Singh S, Gill AAS, Nlooto M, Karpoormath R. Prostate cancer biomarkers detection using nanoparticles based electrochemical biosensors. Biosens Bioelectron. 2019;137:213\u201321. https:\/\/doi.org\/10.1016\/j.bios.2019.03.065.","journal-title":"Biosens Bioelectron"},{"key":"4121_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114100","author":"M Algarra","year":"2025","unstructured":"Algarra M, Vinacua S, Gil-Korilis A, Gil A. Recent developments in the use of carbon-based nanomaterials in cancer therapy. J Control Release. 2025. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114100.","journal-title":"J Control Release"},{"key":"4121_CR121","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6050795","author":"R Panday","year":"2021","unstructured":"Panday R, Abdalla AME, Neupane M, Khadka S, Kricha A, Yang G. Advances in magnetic nanoparticle-driven delivery of gene therapies towards prostate cancer. J Nanomater. 2021. https:\/\/doi.org\/10.1155\/2021\/6050795.","journal-title":"J Nanomater"},{"key":"4121_CR122","doi-asserted-by":"publisher","DOI":"10.1063\/5.0191034","author":"MM Selim","year":"2024","unstructured":"Selim MM, El-Safty S, Tounsi A, Shenashen M. A review of magnetic nanoparticles used in nanomedicine. APL Mater. 2024. https:\/\/doi.org\/10.1063\/5.0191034.","journal-title":"APL Mater"},{"key":"4121_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.matdes.2020.108805","volume":"193","author":"J Ghitman","year":"2020","unstructured":"Ghitman J, Biru EI, Stan R, Iovu H. Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine. Mater Des. 2020;193:108805.","journal-title":"Mater Des"},{"key":"4121_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28155694","author":"F Yanar","year":"2023","unstructured":"Yanar F, Carugo D, Zhang X. Hybrid nanoplatforms comprising organic nanocompartments encapsulating inorganic nanoparticles for enhanced drug delivery and bioimaging applications. Molecules. 2023. https:\/\/doi.org\/10.3390\/molecules28155694.","journal-title":"Molecules"},{"key":"4121_CR125","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1080\/17435889.2024.2405458","volume":"19","author":"RM Pallares","year":"2024","unstructured":"Pallares RM, Kiessling F, Lammers T. Clinical translation of quantum dots. Nanomedicine. 2024;19:2433\u20135.","journal-title":"Nanomedicine"},{"key":"4121_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.dyepig.2022.110784","volume":"208","author":"Q Li","year":"2022","unstructured":"Li Q, Shen X, Xing D. Carbon quantum dots as ROS-generator and -scavenger: a comprehensive review. Dye Pigment. 2022;208:110784.","journal-title":"Dye Pigment"},{"issue":"4","key":"4121_CR127","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/vaccines9040359","volume":"9","author":"TTH Thi","year":"2021","unstructured":"Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: From cancer nanomedicine to COVID-19 vaccines. Vaccines. 2021;9(4):359.","journal-title":"Vaccines"},{"key":"4121_CR128","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/ijms24010787","volume":"24","author":"ED Namiot","year":"2023","unstructured":"Namiot ED, Sokolov AV, Chubarev VN, Tarasov VV, Schi\u00f6th HB. Nanoparticles in clinical trials: analysis of clinical trials, FDA approvals and use for COVID-19 vaccines. Int J Mol Sci. 2023;24:787.","journal-title":"Int J Mol Sci"},{"key":"4121_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12081334","author":"AM Caminade","year":"2022","unstructured":"Caminade AM. Dendrimers, an emerging opportunity in personalized medicine? J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12081334.","journal-title":"J Pers Med"},{"key":"4121_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2025.214493","volume":"179","author":"P Kesharwani","year":"2026","unstructured":"Kesharwani P, Puri V, Alqahtani T, Al Shmrany H, Gupta G, Goh KW, et al. PEGylated dendrimers for precision cancer therapy: advances in tumor targeting, drug delivery, and clinical translation. Biomater Adv. 2026;179:214493.","journal-title":"Biomater Adv"},{"key":"4121_CR131","doi-asserted-by":"publisher","first-page":"128ra39","DOI":"10.1126\/scitranslmed.3003651","volume":"4","author":"J Hrkach","year":"2012","unstructured":"Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4:128ra39.","journal-title":"Sci Transl Med"},{"key":"4121_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells14141052","volume":"14","author":"S Alfei","year":"2025","unstructured":"Alfei S, Reggio C, Zuccari G. Carbon nanotubes as excellent adjuvants for anticancer therapeutics and cancer diagnosis: a plethora of laboratory studies versus few clinical trials. Cells. 2025;14:1\u201358.","journal-title":"Cells"},{"key":"4121_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/bioengineering10010108","volume":"10","author":"SS Lee","year":"2023","unstructured":"Lee SS, Paliouras M, Trifiro MA. Functionalized carbon nanoparticles as theranostic agents and their future clinical utility in oncology. Bioengineering. 2023;10:1\u201328.","journal-title":"Bioengineering"},{"key":"4121_CR134","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.nano.2014.12.016","volume":"11","author":"T Wolfe","year":"2015","unstructured":"Wolfe T, Chatterjee D, Lee J, Grant JD, Bhattarai S, Tailor R, et al. Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo. Nanomed Nanotechnol Biol Med. 2015;11:1277\u201383.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"4121_CR135","first-page":"673","volume":"12","author":"AM Shailendrakumar","year":"2022","unstructured":"Shailendrakumar AM, Tippavajhala VK. Gold and carbon-based nano-theranostics: an overview on the developments and applications for cancer phototherapy. Adv Pharm Bull. 2022;12:673\u201385.","journal-title":"Adv Pharm Bull"},{"key":"4121_CR136","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/02656736.2020.1800831","volume":"37","author":"HF Rodrigues","year":"2020","unstructured":"Rodrigues HF, Capistrano G, Bakuzis AF. In vivo magnetic nanoparticle hyperthermia: a review on preclinical studies, low-field nano-heaters, noninvasive thermometry and computer simulations for treatment planning. Int J Hyperthermia. 2020;37:76\u201399.","journal-title":"Int J Hyperthermia"},{"key":"4121_CR137","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/pharmaceutics13070943","volume":"13","author":"DD Stueber","year":"2021","unstructured":"Stueber DD, Villanova J, Aponte I, Xiao Z, Colvin VL. Magnetic nanoparticles in biology and medicine: past, present, and future trends. Pharmaceutics. 2021;13:943.","journal-title":"Pharmaceutics"},{"key":"4121_CR138","first-page":"151","volume":"3","author":"IL Medintz","year":"2008","unstructured":"Medintz IL, Mattousi H, Clapp AR. Potential clinical applications of quantum dots. Int J Nanomedicine. 2008;3:151\u201367.","journal-title":"Int J Nanomedicine"},{"key":"4121_CR139","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.bioeng.9.060906.152025","volume":"9","author":"S Nie","year":"2007","unstructured":"Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257\u201388.","journal-title":"Annu Rev Biomed Eng"},{"key":"4121_CR140","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1200\/JCO.2024.42.16_suppl.5001","volume":"42","author":"MR Smith","year":"2024","unstructured":"Smith MR, Piulats JM, Todenh\u00f6fer T, Lee J-L, Arranz Arija JA, Mazilu L, et al. CYCLONE 2: a phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2024;42:5001\u20135001.","journal-title":"J Clin Oncol"},{"key":"4121_CR141","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, et al. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J Clin Oncol. 2025;43:1638\u201349.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4121_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020440","volume":"14","author":"C Martori","year":"2022","unstructured":"Martori C, Sanchez-Moral L, Paul T, Pardo JC, Font A, de Porras VR, et al. Macrophages as a therapeutic target in metastatic prostate cancer: a way to overcome immunotherapy resistance? Cancers. 2022;14(2):440. https:\/\/doi.org\/10.3390\/cancers14020440.","journal-title":"Cancers"},{"issue":"6","key":"4121_CR143","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3892\/ijo.2013.1898","volume":"42","author":"JH Han","year":"2013","unstructured":"Han JH, Lee J, Jeon SJ, Choi ES, Cho SD, Kim BY, et al. In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod. Int J Oncol. 2013;42(6):2087\u201393. https:\/\/doi.org\/10.3892\/ijo.2013.1898.","journal-title":"Int J Oncol"},{"key":"4121_CR144","doi-asserted-by":"publisher","DOI":"10.1007\/s44174-025-00445-8","author":"KK Karunakar","year":"2025","unstructured":"Karunakar KK, Cheriyan BV, Shakti H, Kataria K, Yabase L, Nandhini J, et al. Selenium nanoparticles in prostate cancer: a dual-edged sword of therapeutic potential and toxicity. Biomed Mater Devices. 2025. https:\/\/doi.org\/10.1007\/s44174-025-00445-8.","journal-title":"Biomed Mater Devices"},{"key":"4121_CR145","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04604-w","volume":"93","author":"M Catalano","year":"2023","unstructured":"Catalano M, Lapucci A, Nobili S, De Gennaro Aquino I, Vascotto IA, Antonuzzo L, et al. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? Cancer Chemother Pharmacol. 2023;93:1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4121_CR146","doi-asserted-by":"publisher","DOI":"10.34133\/research.0247","author":"AE Zetrini","year":"2023","unstructured":"Zetrini AE, Lip H, Abbasi AZ, Alradwan I, Ahmed T, He C, et al. Remodeling tumor immune microenvironment by using polymer-lipid-manganese dioxide nanoparticles with radiation therapy to boost immune response of castration-resistant prostate cancer. Research. 2023. https:\/\/doi.org\/10.34133\/research.0247.","journal-title":"Research"},{"key":"4121_CR147","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0885328220975249","volume":"36","author":"F Xiao","year":"2021","unstructured":"Xiao F, Liu J, Zheng Y, Quan Z, Sun W, Fan Y, et al. The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics. J Biomater Appl. 2021;36:3\u201314.","journal-title":"J Biomater Appl"},{"key":"4121_CR148","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5c00475","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wei L, Yin X, Xie Y, Gao H, Zhang B, et al. Double-responsive metallic magnetic nanoparticles based on tumor microenvironment \u201cleverage\u201d rebalancing for triple collaborative cancer therapy. Bioconjug Chem. 2025. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5c00475.","journal-title":"Bioconjug Chem"},{"key":"4121_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113714","volume":"155","author":"J Zhao","year":"2022","unstructured":"Zhao J, Zhang C, Wang W, Li C, Mu X, Hu K. Current progress of nanomedicine for prostate cancer diagnosis and treatment. Biomed Pharmacother. 2022;155:113714.","journal-title":"Biomed Pharmacother"},{"key":"4121_CR150","doi-asserted-by":"publisher","first-page":"1902268","DOI":"10.1002\/smll.201902268","volume":"15","author":"A Poddar","year":"2019","unstructured":"Poddar A, Conesa JJ, Liang K, Dhakal S, Reineck P, Bryant G, et al. Encapsulation, visualization and expression of genes with biomimetically mineralized zeolitic imidazolate framework-8 (ZIF-8). Small. 2019;15:1902268.","journal-title":"Small"},{"key":"4121_CR151","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/cells14151136","volume":"14","author":"MA Rauf","year":"2025","unstructured":"Rauf MA, Rao A, Sivasoorian SS, Iyer AK. Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment: a comprehensive review. Cells. 2025;14:1136.","journal-title":"Cells"},{"key":"4121_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-017-0198-3","volume":"36","author":"J Dai","year":"2017","unstructured":"Dai J, Lu Y, Roca H, Keller JM, Zhang J, McCauley LK, et al. Immune mediators in the tumor microenvironment of prostate cancer. Chin J Cancer. 2017;36:1\u20138.","journal-title":"Chin J Cancer"},{"key":"4121_CR153","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10311-017-0670-y","volume":"16","author":"K Divya","year":"2018","unstructured":"Divya K, Jisha MS. Chitosan nanoparticles preparation and applications. Environ Chem Lett. 2018;16:101\u201312.","journal-title":"Environ Chem Lett"},{"key":"4121_CR154","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.70027","volume":"17","author":"WC Chou","year":"2025","unstructured":"Chou WC, Canchola A, Zhang F, Lin Z. Machine learning and artificial intelligence in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025;17:e70027.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04121-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04121-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04121-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:03:12Z","timestamp":1776769392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04121-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":154,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4121"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04121-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any study directly involving any human or animal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Right"}},{"value":"For this type of article, no informed consent is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}